Article
Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update.
Advances in medical sciences - 1 Mar 2016
Njire Moses, Tan Yaoju, Mugweru Julius, Wang Changwei, Guo Jintao, Yew WingWai, Tan Shouyong, Zhang Tianyu
Abstract excerpt
The global control and management of tuberculosis (TB) is faced with the formidable challenge of worsening scenarios of drug-resistant disease. Pyrazinamide (PZA) is an indispensable first-line drug used for the treatment of TB. It plays a key role in reducing TB relapse rates, shortening the course of the disease treatment from 9-12 months to 6 months, and the treatment of patients infected with bacillary...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.